l-DOPA for the prevention and acceleration of the reversal of neurogenic dystrophic damage to internal organs

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This review presents experimental and clinical studies of the effects of the levorotatory isomer of dihydroxyphenylalanine (l-DOPA) on the development and reversal of neurogenic dystrophic changes (neurogenic dystrophy) in the heart, stomach, liver, and pancreas. These changes were induced by stimulation of the reflexogenic zones such as the aortic arch and pyloroduodenal area in rats and rabbits, by tonsillar stimulation in rabbits, by 3-hour electrical stimulation and immobilization in rats, and by central electrical stimulation of the posterior hypothalamus in rabbits. Protective effects of l-DOPA were identified at doses of 30, 50, and 300 mg/kg in terms of the development of biochemical and morphological manifestations of neurogenic dystrophy in the studied organs, including a significant decrease in norepinephrine and creatine phosphate levels and an increase in lactic acid level. The use of l-DOPA during the repair phase accelerated the recovery of adrenergic mediation, energy metabolism, and the resolution of dystrophic morphological manifestations, in particular, hemorrhagic erosions of the gastric mucosa. In clinical settings, preoperative medication of patients with l-DOPA (5 mg/kg) for 3 days before mitral commissurotomy prevented the development of postoperative heart failure. In patients with peptic ulcer disease, the administration of l-DOPA during the early remission phase accelerated the healing of ulcers in the stomach and duodenal wall.

Full Text

Restricted Access

About the authors

Oleg N. Zabrodin

Pavlov First Saint Petersburg State Medical University

Author for correspondence.
Email: ozabrodin@yandex.ru
ORCID iD: 0000-0002-6213-5117

MD, Dr. Sci. (Medicine)

Russian Federation, 6–8 Lva Tolstogo st., Saint Petersburg, 197022

References

  1. Avakyan OM. Effect of catecholamines, their precursors and transformation products on the transmission of excitation from the sympathetic nerve to effectors. In: Proceedings of scientific conference “Regulatory function of biogenic amines”, Leningrad, 1–3 Dec, 1970. Leningrad: [u. b.]; 1970. P. 5–6. (In Russ.)
  2. Anichkov SV, Zavodskaya IS, Moreva EV, et al. Neurogenic dystrophies and their pharmacotherapy. Leningrad: Medicine; 1969. 238 p. (In Russ.)
  3. Baranovsky AYu, Smolyaninov AB, Zavodskaya IS, et al. Preclinical evaluation of the therapeutic efficacy of l-DOPA in chronic gastric ulcers. Pathological physiology and experimental therapy. 1992;36(3):35–37. (In Russ.)
  4. Virabyan TL. Monoaminergic component in the mechanisms of antiulcer action of neurotropic agents [dissertation Abstract]. Yerevan, 1982. 48 p. (In Russ.)
  5. Gomazkov OA. Brain aging and neurotrophins. Cellular and molecular principles of neurotrophic therapy. Moscow: ICAR Publishing House; 2011. 180 p. (In Russ.)
  6. Goncharova VA, Balashova VN, Zavodskaya IS. Effect of exogenous l-DOPA on the state of sympatho-adrenal system of patients with chronic pneumonia with symptoms of diencephalic insufficiency. In: Proceeding of scientific works. Vol. 5: Problems of pulmonology. Leningrad; 1975. P. 79–84. (In Russ.)
  7. Grechishkin LL. Pepsin-forming ability of the gastric mucosa under the action of DOPA and alpha-methyl-DOPA. Pharmacology and toxicology. 1969;32(5):556–558. (In Russ.)
  8. Grokhovsky LP. Biogenic amines (serotonin, catecholamines) and their role in the pathogenesis of peptic ulcer disease and chronic gastritis [dissertation Abstract]. Leningrad; 1972. 30 p. (In Russ.)
  9. Denisik LN. Effectiveness of L-DOPA in peptic ulcer disease. In: Proceeding of scientific works of GIDUV: Modern methods of treatment of gastric and duodenal ulcer disease. Leningrad; 1977. P. 28–29. (In Russ.)
  10. Dorofeev GI, Kozhemyakin LA, Ivashkin VT. Cyclic nucleotides and adaptation of the organism. Leningrad: Nauka; 1978. 182 p. (In Russ.)
  11. Zabrodin ON. Effect of DOPA and reserpine on the development of gastric neurogenic dystrophy. Pharmacology and toxicology. 1969;32(5):559–561. (In Russ.)
  12. Zabrodin ON. Effect of DOPA and tyrosine on healing of gastric wall ulcers and noradrenaline content in it. Bulletin of Experimental Biology and Medicine. 1971;72(10):32–34. (In Russ.)
  13. Zabrodin ON. Pharmacologic analysis of the participation of endogenous noradrenaline in the reverse development of gastric neurogenic dystrophy. Pharmacology and toxicology. 1972;35(5):606–610. (In Russ.)
  14. Zabrodin ON. Role of adrenergic mechanisms in the development and healing of experimental neurogenic lesions of gastric mucosa (pharmacological analysis) [dissertation Abstract]. Leningrad; 1982. 41 p. (In Russ.)
  15. Zabrodin ON. The problem of nerve trophics in the works of S.V. Anichkov and his school. Physiological Journal of the USSR named after I.M. Sechenov. 1993;79(12):109–114. (In Russ.)
  16. Zabrodin ON, Bertash VI. Effect of L-DOPA on healing of neurogenic dystrophic lesions of gastric mucosa in rats. Bulletin of Experimental Biology and Medicine. 1976;82(11):1347–1349. (In Russ.)
  17. Zabrodin ON, Strashnov VI, Zaskalko NI, et al. Comparative evaluation of anesthesia methods for closed mitral commissurotomy. Grekov’s bulletin of surgery. 1981;128(8):75–80. (In Russ.)
  18. Zabrodin ON, Strashnov VI. The role of sympathetic nervous system in the development and prevention of erosive and ulcerative lesions of gastroduodenal mucosa. Messenger of anesthesiology and resuscitation. 2016;13(2):50–56. (In Russ.) EDN: VTNNHV
  19. Zabrodina SK. Norepinephrine and adrenaline content in myocardium and their excretion with urine during cardiac surgeries (Clinical and experimental study) [dissertation Abstract]. Leningrad; 1972. 16 p. (In Russ.)
  20. Zavodskaya IS, Sibirkin NV, Egorova GI, et al. Treatment of peptic ulcer disease with L-DOPA. Therapeutic archive. 1976;48(5):79–82. (In Russ.)
  21. Zavodskaya IS, Moreva EV, Novikova NA. Influence of neurotropic agents on neurogenic heart lesions. Moscow: Medicine; 1977. 192 p. (In Russ.)
  22. Zavodskaya IS, Zabrodin ON, Zaskalko NI. The effect of L’DOPA upon the catecholamines contents, ultrastructure and contractile ability of the myocardium in heart operations. Grekov’s bulletin of surgery. 1978;120(2):13–18. EDN: ZYPMUD
  23. Zavodskaya IS, Moreva EV. Pharmacologic analysis of the mechanism of stress and its consequences. Leningrad: Medicine; 1981; 214 p. (In Russ.)
  24. Zavodskaya IS, Shchedrunov VV, Moreva EV. Effect of levopa on the energy metabolism of the gastric mucosa during treatment of gastric ulcer (a clinico-experimental investigation). Vrachebnoe delo. 1985;(2):26–30. EDN: FMVSDP
  25. Khnychenko LK, Levina LI. l-DOPA in myocardial infarction. The Doctor. 1992;(3):28–29. EDN: TOTATX (In Russ.)
  26. Komarov FI, Zavodskaya IS, Moreva EV, et al. Neurogenic mechanisms of gastroduodenal pathology (experimental and clinical data). Moscow: Medicine; 1984. 240 p. (In Russ.)
  27. Korhov VV. Neurogenic liver dystrophy and its pharmacology. Leningrad: Medicine; 1974. 216 p. (In Russ.)
  28. Krylov AA, Zarembsky RA, Reshetneva EM. Effect of conservative treatment and vagotomy in patients with duodenal ulcers on the components of the cAMP system in the mucosa and gastric contents. Therapeutic archive. 1983;55(9):118–121. (In Russ.)
  29. Lahina KG. Neurogenic cardiac lesions and the effect of L-DOPA on them [dissertation Abstract]. Leningrad; 1973. 21 p. (In Russ.)
  30. Matlina ES, Pukhova GS, Zutler AS. Catecholamine metabolism during DOPA administration to intact rats and muscle load. In: Endocrine mechanisms of regulation of adaptation of the organism to muscular activity. Tartu; 1971. P. 79–95. (In Russ.)
  31. Nilova TN. Pharmacologic analysis of experimental neurogenic damage of the pancreas [dissertation Abstract]. Leningrad; 1985. 17 p. (In Russ.)
  32. Okunevich IV, Sapronov NS. The analysis of the combined aplication of levopa: the contribution of the hypolipidemic property of L-DOPA on the metabolic action in patients with cardiac heart disease. Reviews on Clinical Pharmacology and Drug Therapy. 2011;9(3):65–70. EDN: OUNJPX
  33. Orbeli LA. On some achievements of Soviet physiology: selected works. Vol. 2. Moscow, Leningrad: AS USSR Publ.; 1962. P. 587–606. (In Russ.)
  34. Sklutauskas IG. To the question of pathogenesis of gastric and duodenal ulcer disease. In: Actual questions of gastroenterology and nephrology. Vilnius: Минтис; 1966. P. 138–144. (In Russ.)
  35. Shabak-Spassky PS. Changes in myocardial metabolism and the use of neurotropic agents in tonsillogenic myocardiodystrophy [dissertation Abstract]. Leningrad; 1982. 15 p. (In Russ.)
  36. Shchedrunov VV, Zavodskaya IS, Zabrodin ON. Combined use of central cholinolytic amedine and noradrenaline precursor dioxyphenylalanine (DOPA) in the treatment of peptic ulcer disease. Soviet Medicine. 1975;(2):13–16. (In Russ.)
  37. De Robertis E, Vaz Ferreira A. A multivesicular catechol-containing body of the adrenal medulla of the rabbit. Exp Cell Res. 1957;12(3):575–581. doi: 10.1016/0014-4827(57)90173-8
  38. Doteuchi M. Studies on the experimental gastrointestinal ulcers produced by reserpine and stress. I. Relationship between production of ulcers and changes in tissue monoamines. Jpn J Pharmacol. 1967;17(4):638–647. doi: 10.1254/jjp.17.638
  39. Doteuchi M. Studies on the experimental gastrointestinal ulcers produced by reserpine and stress. Jap J Pharmacol. 1968;18(2):175–184. doi: 10.1254/jjp.18.175
  40. von Euler US, Uddén P. Increase in noradrenaline content of organs after administration of DOPA in the cat. Experientia. 1951;7:465–466. doi: 10.1007/BF02168698
  41. Gey KF, Pletscher A. Distribution and metabolism of DL-3,4-dihydroxy[2-14C]-phenilalanin in rat tissues. Biochem J. 1964;92(2):300–308. doi: 10.1042/bj0920300
  42. Goodall MCC, Kirshner N. Bosynthesis of epinephrine and norepinephrine by sympathetic nerves and ganglia. Circulation. 1958;17(3):366–371. doi: 10.1161/01.cir.17.3.366
  43. Greenacre JK, Coxon A, Petrie A, Reid JL. Comparison of levodopa with carbidopa or benserazide in parkinsonism. Lancet. 1976;308(7982):381–384. doi: 10.1016/s0140-6736(76)92403-x
  44. Kondo T. Levodopa therapy from the neuroprotection viewpoint. J Neurol. 2005;252(S4):32–36. doi: 10.1007/s00415-005-4007-6
  45. Roth RH, Stone EA. The action of reserpine on noradrenaline biosynthesis in sympathetic nerve tissue. Biochem Pharmacol. 1968;17(8):1581–1590. doi: 10.1016/0006-2952(68)90218-9
  46. Schmitt H, Schmitt MH, Fenard S. Localization of the site of the central sympatho-inhibitory action of l-DOPA in dogs and cats. Eur J Pharmacol. 1973;22(2):212–216. doi: 10.1016/0014-2999(73)90016-2
  47. Watanabe AM, Judy WV, Cardon PV. Effect of L-DOPA on blood pressure and sympathetic nerve activity after decarboxylase inhibition in cats. J Pharmacol Exp Ther. 1974;188(1):107–113.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 84654 от 01.02.2023 г.